| Analysts Initiated Coverage for TIE, TEX, MTW, IDIX, GILD |
FyxnewsGilead Sciences (NASDAQ:GILD) Barclays Capital has initiated coverage for Gilead Sciences at Overweight. Gilead Sciences, Inc. is a biopharmaceutical company which discovers, develops and commercializes therapeutics in areas of unmet medical need.
|
| Morgan Stanley Analysts Begin Coverage on Gilead Sciences (GILD) |
Web InquirerResearch analysts at Morgan Stanley (NYSE: MS) started coverage on shares of Gilead Sciences (NASDAQ: GILD) in a report issued on Friday. They set an “overweight” rating on the stock. Separately, analysts at UBS AG (NYSE: UBS) raised their price target ...
|
| Sector Snap: Morgan Stanley on biotech drugmakers |
BusinessWeekA Morgan Stanley analyst said Friday that he believes shares of biotech drugmakers Gilead Sciences, Biogen Idec and Celgene will do well in 2012 because all three companies are poised to report encouraging results for important drug candidates.
|
| Barclays Capital Analysts Initiate Coverage on Gilead Sciences (GILD) |
Web InquirerEquities research analysts at Barclays Capital (NYSE: BCS) assumed coverage on shares of Gilead Sciences (NASDAQ: GILD) in a research note issued to investors on Friday. They set an “overweight” rating and a $67.00 price target on the stock.
|
| Gilead Sciences to Present at Two Upcoming Investor Conferences |
PharmiWeb.com (press release)Gilead Sciences, Inc. (Nasdaq: GILD) today announced that John F. Milligan, PhD, Gilead's President and Chief Operating Officer, will be participating in "fireside chat" forums at two upcoming investor conferences taking place in New York.
|
| Tenofovir failed to meet study endpoints in adolescents with HIV-1 |
Pediatric SuperSiteMarinella Della Negra, MD, and colleagues examined data from two randomly assigned groups of HIV-1-positive adolescents; 45 adolescents received 300 mg of tenofovir (Viread, Gilead Sciences) and 42 received a placebo for 48 weeks.
|
| New low cost HIV drug to be made by Ugandan company |
The Pharma Letter... said that the anti- retroviral (ARV) drug, tenofovir, the active ingredient of US biotech firm Gilead Sciences (Nasdaq: GILD) Viread (tenofovir disoproxil fumarate), will be manufactured by local company Quality Chemicals Pharmaceutical Company.
|
